Clinical Trials | December 03, 2025
AbbVie’s Atogepant shows breakthrough results for acute migraine relief
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Now a test that offers new precision in prostate cancer detection
Patients can now get the starting 2.5 mg dose for $299 per month
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Roche says the move marks a step forward in its digital transformation strategy
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
